Status:
TERMINATED
Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
Lead Sponsor:
PeriPharm
Collaborating Sponsors:
Personalized Medicine Partnership for Cancer
Jewish General Hospital
Conditions:
Non-small Cell Lung Cancer Metastatic
Eligibility:
All Genders
18+ years
Brief Summary
This is a phase IV multicenter trial to evaluate the pharmacoeconomic (PE) impact of crizotinib and its companion diagnostic test used in a real-life setting in advanced ALK-positive non-small cell lu...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with histologically confirmed locally advanced or metastatic NSCLC
- Presence of the ALK-fusion oncogene (ALK+) as determined using a validated testing platform
- Planned first or second-line treatment with crizotinib
- Signed and dated IRB-approved informed consent document
- Ability to read and understand English or French
- 18 years of age or older
Exclusion
Key Trial Info
Start Date :
February 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT02228421
Start Date
February 1 2015
End Date
March 1 2020
Last Update
March 11 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
2
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
3
CSSS de Rimouski-Neigette
Rimouski, Quebec, Canada, J5L 5T1